



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Ye, *et al.*

Appl. No.: 10/755,854

Filed: January 13, 2004

For: **Eosinophil-Derived Neurotoxin as a
Marker for Ovarian Cancer**

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7570/80962

Supplemental Information Disclosure Statement

Commissioner of Patents
U.S. Patent and Trademark Office
220 20th Street South
Customer Window, **MS Amendment**
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Submitted herewith is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the listed document are also enclosed with the exception of the United States patents.

Applicants also wish to make the Examiner aware of co-pending applications 09/948,094, filed September 7, 2001; 10/162,221, filed on June 5, 2002; and 10/869,027, filed on June 17, 2004.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.



Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.

Applicants do not believe any fees are due for the submission of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7570/80962.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo
Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicants

Date August 12, 2004
1801 K Street, N.W., Suite 401L
Washington, DC 20006-1201
Phone: (202) 419-7013



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Atty. Docket No.: 7570/80962

Appl. No.: 10/755,854


Applicant(s) Ye, *et al.*

Filing Date: January 13, 2004

Group: to be assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A 1	5,604,106	Feb. 18, 1997	Liotta, <i>et al.</i>	435	7.23	May 18, 1993
	A 2	5,695,761	Dec. 9, 1997	Denhardt, <i>et al.</i>	424	184.1	Dec. 23, 1993
	A 3	5,712,104	Jan. 27, 1998	Yamamoto	435	7.92	Jan. 6, 1997
	A 4	5,801,004	Sep. 1, 1998	Hudson, <i>et al.</i>	435	7.23	Dec. 23, 1996
	A 5	6,414,219 B1	Jul. 2, 2002	Denhardt, <i>et al.</i>	800	18	Jun. 30, 1999
	A 6	6,686,444 B2	Feb. 3, 2004	Ashkar	530	329	Aug. 21, 1997
	A 7	2002/0039753 A1	Apr. 4, 2002	Chai, <i>et al.</i>	435	7.23	Jan. 5, 2001
	A 8	2002/0052308 A1	May 2, 2002	Rosen, <i>et al.</i>	514	1	Aug. 10, 2001
	A 9						
	A 10						
	A 11						
	A 12						
	A 13						
	A 14						
	A 15						
	A 16						
	A 17						
	A 18						
	A 19						
	A 20						
	A 21						
	A 22						
	A 23						
	A 24						
	A 25						
	A 26						
	A 27						
Examiner				Date Considered			



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.: 7570/80962

Appl. No.: 10/755,854


Applicant(s) Ye, et al.

Filing Date: January 13, 2004

Group: to be assigned

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Abst./Trans.	
							Yes	No
	B 1							
	B 2							
	B 3							
	B 4							
	B 5							
	B 6							
	B 7							
	B 8							
	B 9							
	B 10							
	B 11							
	B 12							
	B 13							
	B 14							
	B 15							
	B 16							
	B 17							
	B 18							
	B 19							
	B 20							
	B 21							
	B 22							
	B 23							
	B 24							
	B 25							
	B 26							
	B 27							
Examiner				Date Considered				

 <p>LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p>		Atty. Docket No.: 7570/80962	Appl. No.: 10/755,854
		Applicant(s) Ye, et al.	
		Filing Date: January 13, 2004	Group: to be assigned
Examiner Initial	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C 1	BAST, et al., "A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer," <i>N. Engl. J. Med.</i> 309:883-887 (1983).	
	C 2	BERTEAU, et al., "Prostasin mRNA to Detect Prostate Cells in Blood of Cancer Patients," <i>Clin. Chem. Lab. Med.</i> 37:S119 (1999).	
	C 3	CHEN, et al., "Down-Regulation of Prostasin Serine Protease: A Potential Invasion Suppressor in Prostate Cancer," <i>Prostate</i> 48:93-103 (2001).	
	C 4	CHEN, et al., "Prostasin Serine Protease Inhibits Breast Cancer Invasiveness and Is Transcriptionally Regulated by Promoter DNA Methylation," <i>Int. J. Cancer</i> 97:323-329 (2002).	
	C 5	CHEUNG, et al., "Identify Metastasis-Associated Genes in Hepatocellular Carcinoma through Clonality Delineation for Multinodular Tumor," <i>Cancer Res.</i> 62:4711-4721 (2002).	
	C 6	COOLEN, et al., "Elevation of Brain-Type Creatine Kinase in Serum from Patients with Carcinoma," <i>Cancer</i> 44:1414-1418 (1979).	
	C 7	CRAMER, et al., "Carotenoids, Antioxidants and Ovarian Cancer Risk in Pre- and Postmenopausal Women," <i>Int. J. Cancer</i> 94:128-134 (2001).	
	C 8	DALY, et al., "The Search for Predictive Patterns in Ovarian Cancer: Proteomics Meets Bioinformatics," <i>Cancer Cell</i> 1:111-112 (2002).	
	C 9	DENHARDT, et al., "Osteopontin: A Protein with Diverse Functions," <i>FASEB J.</i> 7:1475-1482 (1993).	
	C 10	DeRISI, et al., "Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer," <i>Nature Genetics</i> 14:457-460 (1996).	
	C 11	FISH, et al., "Changes in Serum Acute Phase Proteins in Ovarian Cancer Patients Receiving Cis-Diamminedichloroplatinum (CDDP) Infusion Therapy," <i>Clinical Biochem.</i> 17:39-41 (1984).	
	C 12	FISH, et al., "Serum Haptoglobin and α 1-Acid Glycoprotein as Indicators of the Effectiveness of cis-Diamminedichloroplatinum (CDDP) in Ovarian Cancer Patients - a Preliminary Report," <i>Eur. J. Cancer Clin. Oncol.</i> 20:625-630 (1984).	
	C 13	GIACHELLI, et al., "Molecular and Cellular Biology of Osteopontin," <i>Trends Cardiovasc. Med.</i> 5:88-95 (1995).	
	C 14	GINGRICH, et al., "Metastatic Prostate Cancer in a Transgenic Mouse," <i>Cancer Res.</i> 56:4096-4102 (1996).	
	C 15	HARVEY, et al., "Cancer Cells Release a Covalent Complex Containing Disulfide-Linked Domains from Urinary Plasminogen Activator, Neural Cell Adhesion Molecule, and Haptoglobin α and β Chains," <i>Arch. Biochem. Biophys.</i> 345:289-298 (1997).	
	C 16	HEID, et al., "Real Time Quantitative PCR," <i>Genome Res.</i> 6:986-994 (1996).	
	C 17	HOOPER, et al., "Testisin, a New Human Serine Proteinase Expressed by Premeiotic Testicular Germ Cells and Lost in Testicular Germ Cell Tumors," <i>Cancer Res.</i> 59:3199-3205 (1999).	
	C 18	HOOPER, et al., "Localization, Expression and Genomic Structure of the Gene Encoding the Human Serine Protease Testisin," <i>Biochimica et Biophysica Acta</i> 1492:63-71 (2000).	
	C 19	KIBEL, et al., "Loss of Heterozygosity at 12P12-13 in Primary and Metastatic Prostate Adenocarcinoma," <i>J. Urol.</i> 164:192-196 (2000).	
Examiner		Date Considered	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Atty. Docket No.: 7570/80962	Appl. No.: 10/755,854
		Applicant(s) Ye, et al.	
		Filing Date: January 13, 2004	Group: to be assigned
Examiner Initial			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
	C 20	KIEFER, et al., "The cDNA and Derived Amino Acid Sequence for Human Osteopontin," <i>Nuc. Ac. Res.</i> 17:3306 (1989).	
	C 21	KIM, et al., "Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer," <i>JAMA</i> 287:1671-1679 (2002).	
	C 22	KO, et al., "Haptoglobin Typing and Quantitation in Normal Chinese Females and Gynecologic Cancer Patients," <i>Chinese J. Microbiol. Immunol.</i> 13:149-157 (1980).	
	C 23	KO, et al., "Haptoglobin Typing and Quantitation in Normal Chinese Females and Gynecologic Cancer Patients," <i>Chinese J. Microbiol. Immunol.</i> 13:149-157 (1980) Abstract; Database Medline, Accession No. 81089629.	
	C 24	KURTZ, et al., "Serum Creatine Kinase BB Isoenzyme as a Diagnostic Aid in Occult Small Cell Lung Cancer," <i>Cancer</i> 56:562-566 (1985).	
	C 25	MILLS, et al., "Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics," <i>J. Natl. Cancer. Inst.</i> 93:1437-1439 (2001).	
	C 26	MOK, et al., "Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology," <i>J. Natl. Cancer Inst.</i> 93:1458-1464 (2001).	
	C 27	MOK, et al., "Molecular Cloning of Differentially Expressed Genes in Human Epithelial Ovarian Cancer," <i>Gynecologic Oncol.</i> 52:247-252 (1994).	
	C 28	MOK, et al., "SPARC, an Extracellular Matrix Protein with Tumor-Suppressing Activity in Human Ovarian Epithelial Cells," <i>Oncogene</i> 12:1895-1901 (1996).	
	C 29	MÜELLER-PILLASCH, et al., "Cloning of a Gene Highly Overexpressed in Cancer Coding for a Novel KH-Domain Containing Protein," <i>Oncogene</i> 14:2729-2733 (1997).	
	C 30	OLDBERG, et al., "Cloning and Sequence Analysis of Rat Bone Sialoprotein (Osteopontin) cDNA Reveals an Arg-Gly-Asp Cell-Binding Sequence," <i>Proc. Natl. Acad. Sci. USA</i> 83:8819-8823 (1986).	
	C 31	OLDBERG, et al., "Identification of a Bone Sialoprotein Receptor in Osteosarcoma Cells," <i>J. Biol. Chem.</i> 263:19433-19436 (1988).	
	C 32	PATARCA, et al., "Differential Induction of Interferon γ Gene Expression after Activation of CD4 ⁺ Cells by Conventional Antigen and Mls Superantigen," <i>Proc. Natl. Acad. Sci. USA</i> 88:2736-2739 (1991).	
	C 33	PENG, et al., "Proteomics: The Move to Mixtures," <i>J. Mass Spectrom.</i> 36:1083-1091 (2001).	
	C 34	PETRICOIN, et al., "Use of Proteomic Patterns in Serum to Identify Ovarian Cancer," <i>Lancet</i> 359:572-577 (2002).	
	C 35	PIVA, et al., "Interleukin-6 Differentially Stimulates Haptoglobin Production by Peritoneal and Endometriotic Cells <i>in Vitro</i> : A Model for Endometrial-Peritoneal Interaction in Endometriosis," <i>J. Clin. Endocrinol. Metab.</i> 86:2553-2561 (2001).	
	C 36	REN, et al., "Reduced Lysyl Oxidase Messenger RNA Levels in Experimental and Human Prostate Cancer," <i>Cancer Res.</i> 58:1285-1290 (1998).	
	C 37	SCHNEIDER, et al., "Osteopontin But Not Osteonectin Messenger RNA Expression Is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer," <i>Clin. Cancer Res.</i> 10:1588-1596 (2004).	
	C 38	SCHRIML, et al., "Tyramide Signal Amplification (TSA)-FISH Applied to Mapping PCR-Labeled Probes Less Than 1 kb in Size," <i>BioTechniques</i> 27:608-613 (1999).	
Examiner		Date Considered	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Atty. Docket No.: 7570/80962	Appl. No.: 10/755,854
		Applicant(s) Ye, et al.	
		Filing Date: January 13, 2004	Group: to be assigned
<div>Examiner Initial</div> <div>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</div>			
	C 39	SCHUMMER, et al., "Comparative Hybridization of an Array of 21 500 Ovarian cDNAs for the Discovery of Genes Overexpressed in Ovarian Carcinomas," <i>Gene</i> 238:375-385 (1999).	
	C 40	SENGER, et al., "Elevated Expression of Secreted Phosphoprotein I (Osteopontin, 2ar) as a Consequence of Neoplastic Transformation," <i>Anticancer Res.</i> 9:1291-1300 (1989).	
	C 41	SHARP, et al., "Tumor Cells Are the Source of Osteopontin and Bone Sialoprotein Expression in Human Breast Cancer," <i>Lab. Investig.</i> 79:869-877 (1999).	
	C 42	SHINDO, "Haptoglobin Subtyping with Anti-Haptoglobin.Alpha.Chain Antibodies," <i>Electrophoresis</i> 11:483-488 (1990), see especially Abstract; Database Caplus, Accession No. 1990:548290, (Sch. Med. Akita Univ., Hondo, Japan).	
	C 43	SMITH, et al., "Molecular Cloning of a Tumor Promoter-Inducible mRNA Found in JB6 Mouse Epidermal Cells: Induction Is Stable at High, but Not at Low, Cell Densities," <i>J. Cell. Biochem.</i> 34:13-22 (1987).	
	C 44	SZALA, et al., "Molecular Cloning of cDNA for the Carcinoma-Associated Antigen GA733-2," <i>Proc. Natl. Acad. Sci. USA</i> 87:3542-3546 (1990).	
	C 45	THOMPSON, et al., "Increased Fucosylation and Other Carbohydrate Changes in Haptoglobin in Ovarian Cancer," <i>Cancer Letters</i> 66:43-48 (1992).	
	C 46	TUCK, et al., "Osteopontin Induces Increased Invasiveness and Plasminogen Activator Expression of Human Mammary Epithelial Cells," <i>Oncogene</i> 18:4237-4246 (1999).	
	C 47	VLAHOU, et al., "Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine," <i>Am. J. Pathol.</i> 158:1491-1502 (2001).	
	C 48	WANG, et al., "Monitoring Gene Expression Profile Changes in Ovarian Carcinomas Using cDNA Microarray," <i>Gene</i> 229:101-108 (1999).	
	C 49	YE, et al., "Identification and Validation of Urinary Biomarkers for Early Stage of Ovarian Cancer by Multiple Proteomic Approaches," <i>Proc. Am. Assoc. Cancer Res.</i> 45:915 (abstract 3964 (2004)).	
	C 50	YIU, et al., "Prostasin, a Potential Serum Marker for the Early Detection of Ovarian Cancer," <i>Proceedings of the American Association for Cancer Research Annual</i> 42:744 (2001).	
	C 51	YU, et al., "Prostasin Is a Novel Human Serine Proteinase from Seminal Fluid," <i>J. Biol. Chem.</i> 269:18843-18848 (1994).	
	C 52	YU, et al., "Molecular Cloning, Tissue-Specific Expression, and Cellular Localization of Human Prostasin mRNA," <i>J. Biol. Chem.</i> 270:13483-13489 (1995).	
	C 53	ZHAU, et al., "Biomarkers Associated with Prostate Cancer Progression," <i>J. Cell. Biochem. Supp.</i> 19:208-216 (1994).	
	C 54		
	C 55		
	C 56		
	C 57		
Examiner		Date Considered	